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Reversible endotension associated with excessive
warfarin anticoagulation
Vikram S. Iyer, MD, Kent S. MacKenzie, MD, Marc-Michel Corriveau, MD,
and Oren K. Steinmetz, MD, Montréal, Québec, Canada
An aortic aneurysm was successfully treated with an endovascular stent graft, with no evidence of endoleak and
documented progressive aortic diameter reduction during the first 23 months. At 29 months, the patient had
documented enlargement of the aneurysm sac associated with excessive anticoagulation with warfarin. No evidence of
endoleak could be demonstrated with any diagnostic modality. Progressive aneurysm sac diameter regression was
documented after reversal of excessive anticoagulation to therapeutic levels (international normalized ratio of 2 to 3).
Strict monitoring of coagulation profile in patients after endovascular aneurysm repair requiring anticoagulation with
warfarin is recommended to avoid this complication, which to our knowledge has not been previously reported. (J Vasc
Surg 2007;45:600-2.)Successful endovascular aortic aneurysm repair (EVAR)
results in exclusion of the aneurysm sac from the circula-
tion. Endoleak is the term used to describe incomplete
aneurysm exclusion or ongoing perfusion of the aneurysm
sac.1 In patients with successful aneurysm exclusion, aneu-
rysm size generally decreases over time. However, reduc-
tion in aneurysm sac diameter does not usually occur in the
presence of a persistent endoleak, and in some cases, the
aneurysm diameter increases.2-4
Aneurysm enlargement in the absence of endoleak has
also been reported, and the term endotension, is used to
describe this phenomenon.5 Possible causes of endotension
have been outlined6 and include pressure transmission to
the aneurysm sac around the ends of the graft, through the
graft wall, or from branch vessels, as well as pressure
buildup from fluid accumulation in the aneurysm sac.
Anticoagulation with warfarin because of coexisting
medical conditions is a requirement in up to 15% of patients
undergoing EVAR.7 Slower rates of sac shrinkage have
been shown in warfarin-treated patients,7 as have lower
rates of spontaneous thrombosis of endoleaks.7,8 We de-
scribe a case of post-EVAR endotension that appeared to be
related to over-anticoagulation with warfarin. This process
was reversible by resumption of normal therapeutic warfa-
rin levels and did not require any other intervention.
CASE REPORT
A 77-year-old man with a history of coronary artery disease,
cardiac arrhythmias, and treated hypertension presented with a
large infrarenal abdominal aortic aneurysm (AAA). The AAA had a
anteroposterior (AP) diameter of 69 mm and a transverse (T)
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600diameter of 68 mm. He was on long-term anticoagulation with
warfarin for his cardiac disease.
Because of his cardiac disease, the patient was considered high
risk for open repair and was treated with EVAR. He was operated
on electively after full reversal of his oral anticoagulation. The
infrarenal aortic neck was 20 mm in length and 24 mm in diameter
with no angulation, and the distal common iliac diameters were
both 12 mm. A Talent bifurcated endograft (Medtronic, Santa
Rosa, Calif) with a suprarenal fixation was selected and introduced
through bilateral femoral artery cutdowns. The main body, which
had a proximal diameter of 28 mm, a distal iliac diameter of 14 mm
and a length of 170 mm, was introduced from the left common
femoral artery. The contralateral iliac limb was 67 mm long with a
distal diameter of 14mm. The right internal iliac artery origin was
covered accidentally during graft deployment. The intraopera-
tive angiogram revealed a delayed type II leak through lumbar
collaterals
The patient resumed his oral anticoagulation and had a
follow-up computed tomography (CT) scan 1 week later, which
revealed no endoleak. At 1 month, there was no change in the size of
the aneurysm. The patient was then followed up every 6months with
CT scans, and aCT scan at 23months showed the aneurysmdiameter
had decreased progressively in size to 54 mm AP 55 mm T.
At 29 months postprocedure, he presented with dyspnea,
fatigue and subconjunctival hemorrhages. His hemoglobin level
dropped from 14.8 to 11.8 g/dL, and his international normalized
ratio (INR) was markedly elevated to 16.9. The elevation in INR
was attributed to an error in his warfarin prescription, which he
filled while vacationing outside of the country. At presentation, his
blood pressure and heart rhythm were both well controlled and no
other changes had occurred in the medical control of his cardio-
vascular risk factors. A three-phase CT scan, consisting of a plain
sequence, followed by one with contrast and a delayed sequence
3 minutes later, showed an increase in aneurysm maximal diameter
to 61 mm AP  70 mm T diameter. No endoleak was visualized.
The patient was given fresh frozen plasma to correct his
coagulopathy and subsequently underwent a diagnostic angiogra-
phy (Fig 1), which included selective mesenteric and internal iliac
artery angiograms, all of which failed to demonstrate an endoleak.
An ultrasound scan of the abdomen and pelvis with Doppler
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endoleak. His INR was then maintained between 1.5 and 2.0, and
another CT scan with contrast was repeated 3 months later. His
aneurysm then decreased in size to 55 mm AP  59 mm T at 32
months and 53 mm AP 53 mm T at 35 months. No evidence of
endoleak was detected on subsequent scans (Fig 2).
DISCUSSION
The goal of EVAR in treatment of an AAA is to prevent
death from aneurysm rupture. In most cases, proper posi-
tioning of the stent graft results in exclusion of the aneu-
rysm sac from the circulation and depressurization of the
aneurysm sac. Chuter et al9 showed that aneurysm sac
pressures were significantly lower in patients whose AAAs
were successfully excluded with a stent graft. In the
presence of endoleak, however, others found that intra-
aneurysmal pressure remains high.10,11
Endotension is the term adopted to describe the con-
dition of increasing aneurysm sac diameter in the absence of
an endoleak. In some cases of endotension, elevated aneu-
Fig 1. Aortogram demonstrates the patent bifurcated endograft
with absence of endoleak.rysm sacs are pressures have been demonstrated and aneu-rysm rupture can occur.12 The cause of endotension is still
unclear. This is apparent in its changing definition and
classification. At a recent 27-member international confer-
ence, endotension was defined as “increased intrasac pres-
sure after EVAR without visualized endoleak on delayed
contrast CT scans.”13 Endotension was further classified as
type A, with no endoleak; B, with sealed endoleak (virtual
endoleak); C, with type I or type III leak (detectable only
on opening the aneurysm sac); and D, with type II leak
(detectable only on opening the aneurysm sac).
A prevailing opinion (16/26 [61.5%]) at this meeting
was that endotension indicated the presence of a sealed or
clotted endoleak. This concept is supported by some oper-
ative findings where endografts have been explanted owing
to endotension. In some cases, gel-like semi-liquid throm-
bus has been documented at proximal, distal, and junc-
tional seal zones,12 and in others, back-bleeding has been
found from lumbar vessels upon removal of this throm-
bus.14 It has also been noted, however, that some patients
with endotension have no obvious thrombus in the intra-
aneurysmal sac, but instead a clear straw-colored liquid is
found.14,15 These seromas or “sac hygromas” may be the
result of ultrafiltration through graft material, as proposed
by Williams,16 or hyperfibrinolysis, which is supported by
high levels of thrombolytic factors and products of fibrino-
lysis in the sac fluid.15 Low-grade infection is another
possibility.6
Some authors believe that endotension represents a
low-flow endoleak that is not detected with current imag-
ing methods,17,18 despite the absence of visible bleeding
from the open aneurysm sac.14,15,17 To date, there is no
overwhelming evidence to support one hypothesis over
another in all cases, and the etiology is likely multifactorial.
In the present report, excessive warfarin anticoagula-
tion was temporally related to the development of endo-
tension. Endotension resolved and sac diameter clearly
regressed progressively when warfarin levels were lowered
and the INR was maintained in a therapeutic range. How
this fits in to any of the above hypotheses is not clear.
Warfarin use has been associated with AAA rupture in a
patient previously treated with an endograft,19 and antico-
agulation was suggested as a possible mechanism for per-
sistent endoleak.
Fairman et al7 reported that spontaneous thrombosis of
type II endoleaks may be less likely in patients taking
warfarin. Similarily, Biebl et al8 found that among patients
with de novo endoleaks, spontaneous resolution occurred
in 0% of warfarin-treated patients vs 12.8% of controls.
Statistical significance was not reached in either study;
however, that may be a result of type II error. Fairman et al7
did find a significantly lower mean percent reduction in
aneurysm sac diameter at 1 year of 7.6% in patients taking
warfarin compared with 17.5% in patients not taking war-
farin; however, this was not supported by Biebl et al.8
Neither study found an increased rate of early or delayed
postoperative endoleak associated with warfarin use.
levels
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Our case demonstrates an apparent role of over-
anticoagulation with the development of endotension. Al-
though the mechanism is not clear, correction of the exces-
sive over-anticoagulation and maintaining a therapeutic
level resulted in progressive aneurysm sac diameter reduc-
tion. Strict monitoring of coagulation profile in patients
after EVAR requiring anticoagulation with warfarin is rec-
ommended to avoid this condition, which to our knowl-
edge has not been previously reported.
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